OverviewSuggest Edit

Proteostasis Therapeutics is a biopharmaceutical company developing therapeutics to treat diseases caused by an imbalance in the proteostasis network. It specializes in the medicines for cystic fibrosis as well as treatments for the unfolded protein response dysfunction.
TypePublic
Founded2006
HQBoston, MA, US
Websiteproteostasis.com
Employee Ratings3.2

Latest Updates

Employees (est.) (Mar 2020)44(-34%)
Revenue (FY, 2020)$6.9 M(+38%)
Share Price (Dec 2020)$22.2
Cybersecurity ratingBMore

Key People/Management at Proteostasis Therapeutics

David Arkowitz

David Arkowitz

Director
Richard Peters

Richard Peters

President, CEO, and Director
Ellen K. Forest

Ellen K. Forest

Chief Human Resources Officer
Kim Cobleigh Drapkin

Kim Cobleigh Drapkin

Director
Brigitte Robertson

Brigitte Robertson

Chief Medical Officer
Paulash Mohsen

Paulash Mohsen

Chief Business Officer
Show more

Proteostasis Therapeutics Office Locations

Proteostasis Therapeutics has an office in Boston
Boston, MA, US (HQ)
80 Guest St 5th floor
Show all (1)

Proteostasis Therapeutics Financials and Metrics

Proteostasis Therapeutics Revenue

Proteostasis Therapeutics's revenue was reported to be $6.9 m in FY, 2020
USD

Revenue (Q1, 2021)

3.5m

Net income (Q1, 2021)

(8.7m)

EBIT (Q1, 2021)

(9.3m)

Market capitalization (24-Dec-2020)

2.9m

Closing stock price (24-Dec-2020)

22.2

Cash (31-Mar-2021)

52.1m

EV

(16.2m)
Proteostasis Therapeutics's current market capitalization is $2.9 m.
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

8.4m5.3m2.8m5.0m6.9m

General and administrative expense

11.9m11.7m15.7m13.8m11.9m

R&D expense

34.0m53.7m50.3m52.3m22.3m

Operating expense total

45.8m65.3m66.0m66.2m34.2m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Revenue

1.2m1.5m1.7m1.0m1.1m1.6m942.0k843.0k1.1m5.0m3.5m

General and administrative expense

2.3m3.1m3.3m3.2m2.9m2.7m3.8m4.0m4.2m3.9m3.7m3.2m3.6m4.4m4.5m6.1m

R&D expense

6.9m7.4m9.2m13.1m15.4m12.9m8.4m12.6m15.6m16.1m16.9m10.1m6.5m4.6m1.2m6.8m

Operating expense total

9.2m10.5m12.5m16.3m18.3m15.6m12.2m16.6m19.7m20.1m20.6m13.3m10.1m9.0m5.8m12.8m
Annual
USDFY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

18.6m29.7m28.8m25.0m80.8m

Accounts Receivable

668.0k

Prepaid Expenses

4.1m1.4m2.5m1.4m2.3m

Current Assets

90.2m76.1m120.9m70.9m87.6m
Quarterly
USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

49.8m42.6m43.8m15.4m23.9m18.2m19.5m19.9m19.7m31.6m28.6m35.3m33.4m42.9m35.8m52.1m

Accounts Receivable

136.0k140.0k445.0k710.0k730.0k1.1m

Prepaid Expenses

824.0k1.1m2.4m3.7m2.8m1.8m2.0m2.1m1.9m3.1m3.1m1.9m2.5m2.0m821.0k3.8m

Current Assets

50.8m43.9m103.1m74.6m61.5m46.4m65.6m63.0m48.3m108.5m91.1m79.7m59.6m50.8m41.6m66.6m
USDQ1, 2016

Revenue/Employee

27.6k

Financial Leverage

1.3 x
Show all financial metrics

Proteostasis Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Yumanity TherapeuticsAugust 24, 2020$500 m

Proteostasis Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

SecurityScorecard logo

Proteostasis Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Proteostasis Therapeutics Online and Social Media Presence

Embed Graph

Proteostasis Therapeutics News and Updates

PROTEOSTASIS MERGER INVESTIGATION: Halper Sadeh LLP Announces Investigation Into Whether The Merger of Proteostasis Therapeutics, Inc. is Fair to Shareholders; Investors are Encouraged to Contact The Firm

NEW YORK, Aug. 25, 2020 /PRNewswire/ -- Halper Sadeh LLP, a global investor rights law firm, is investigating whether Proteostasis Therapeutics, Inc. (NASDAQ: PTI) and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders in...

Yumanity backs onto Wall Street via Proteostasis merger

On the heels of a Big Pharma deal worth up to $500 million, Yumanity Therapeutics is merging its way onto Wall Street. The neuro-focused biotech is joining up with Proteostasis, which once planned to move a cystic fibrosis drug into the clinic this year but is now looking for someone to buy its pipe…

Proteostasis Therapeutics Frequently Asked Questions

  • When was Proteostasis Therapeutics founded?

    Proteostasis Therapeutics was founded in 2006.

  • Who are Proteostasis Therapeutics key executives?

    Proteostasis Therapeutics's key executives are David Arkowitz, Richard Peters and Ellen K. Forest.

  • How many employees does Proteostasis Therapeutics have?

    Proteostasis Therapeutics has 44 employees.

  • What is Proteostasis Therapeutics revenue?

    Latest Proteostasis Therapeutics annual revenue is $6.9 m.

  • What is Proteostasis Therapeutics revenue per employee?

    Latest Proteostasis Therapeutics revenue per employee is $156.7 k.

  • Who are Proteostasis Therapeutics competitors?

    Competitors of Proteostasis Therapeutics include Maruishi Pharmaceutical, Laboratoires Thea and ViiV Healthcare.

  • Where is Proteostasis Therapeutics headquarters?

    Proteostasis Therapeutics headquarters is located at 80 Guest St 5th floor, Boston.

  • Where are Proteostasis Therapeutics offices?

    Proteostasis Therapeutics has an office in Boston.

  • How many offices does Proteostasis Therapeutics have?

    Proteostasis Therapeutics has 1 office.